AORTIC DILATION & MARFAN SYNDROME

主动脉扩张

• 批准号: 6265867
• 负责人: DAVID SILVERMAN
• 金额: $ 1.91万
• 依托单位: UNIVERSITY OF CONNECTICUT SCH OF MED/DNT
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6265867
• 关键词: Marfan syndrome; aorta disorder; beta antiadrenergic agent; cardiovascular disorder chemotherapy; clinical research; drug screening /evaluation; elasticity; human subject; human therapy evaluation; vasodilatation; verapamil

The aims of this study are to evaluate the efficacy of long term treatment with long acting verapamil in delaying aortic root dilation in patients with Marfan syndrome, and to evaluate the effect of treatment with verapamil and metoprolol on the elastic properties of the aorta in patients with Marfan syndrome. The information to be gained from this study may have significant clinical impact on the treatment of patients with the Marfan syndrome. Currently, there is no acceptable alternative to beta-blocker treatment for delaying the progression of aortic root dilation in afflicted patients. An alternative therapy for retardation of aortic dilatation for patients who cannot receive beta-adrenergic receptor antagonists could have a substantial impact upon their morbidity and mortality. This study may determine whether verapamil represents such an alternative.

本研究的目的是评估长效维拉帕米长期治疗延迟马凡综合征患者主动脉根部扩张的疗效，并评估维拉帕米和美托洛尔治疗对马凡综合征患者主动脉弹性的影响。 从这项研究中获得的信息可能对马凡综合征患者的治疗产生重大的临床影响。 目前，尚无可接受的β受体阻滞剂治疗替代方案来延缓患者主动脉根部扩张的进展。 对于不能接受β-肾上腺素能受体拮抗剂的患者来说，延迟主动脉扩张的替代疗法可能对其发病率和死亡率产生重大影响。 这项研究可能会确定维拉帕米是否代表这种替代方案。